<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502280</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#10BN132</org_study_id>
    <nct_id>NCT01502280</nct_id>
  </id_info>
  <brief_title>Fluorescence-guided Surgery for Low- and High-grade Gliomas</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>Barrow 5-ALA Intraoperative Confocal Evaluation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gliomas are the most common primary brain tumor, yet remain a challenge to effectively treat.&#xD;
      Mounting evidence suggests that survival improves with greater tumor removal, yet being able&#xD;
      do a complete removal can be difficult due to the tumor's infiltrating nature.&#xD;
      5-aminolevulinic acid (5-ALA) is a natural compound that, when patients take it by mouth 3&#xD;
      hours before surgery, is selectively taken up by glioma cells and causes a red/pink&#xD;
      fluorescence (glow) under a blue light that allows tumor margins to be seen during the course&#xD;
      of surgery. While this compound is used as a standard-of-care agent in Europe, it remains&#xD;
      under testing by the Food and Drug Administration (FDA). A recent clinical trial in Germany,&#xD;
      however, has demonstrated a significant improvement in the rate of complete resection for&#xD;
      certain brain tumors (65% vs. 34%).&#xD;
&#xD;
      The Barrow 5-ALA Intraoperative Confocal (BALANCE) Trial will measure the effect of 5-ALA on&#xD;
      the amount of glioma tumor removal. To improve the usefulness of 5-ALA, a new special&#xD;
      microscope fitted with a blue light, will be used to magnify microscopic fluorescence at the&#xD;
      tumor margins. The investigators' hypothesis is that 5-ALA fluorescence with the use of the&#xD;
      special microscope during surgery will greatly lower the amount of tumor left behind.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gliomas are the most common primary brain tumor, yet are associated with a 12-14 month&#xD;
      overall survival in the United States. Mounting evidence suggests that survival improves with&#xD;
      greater extent of resection, yet achieving a complete radiographic resection is challenging&#xD;
      due to the tumor's infiltrating nature. Oral 5-aminolevulinic acid (5-ALA/Gliolan®) is a&#xD;
      natural compound that, when administered to patients within 3 hours prior to surgery, is&#xD;
      selectively metabolized by glioma cells and induces a red/pink fluorescence under blue light&#xD;
      that facilitates intraoperative identification of tumor margins. While this compound is used&#xD;
      as a standard-of-care agent in Europe, it remains under examination by the Food and Drug&#xD;
      Administration (FDA). A recent multicenter randomized, single-blind, controlled study in&#xD;
      Germany demonstrated a significant improvement in the rate of complete resection for&#xD;
      high-grade gliomas, as compared to conventional microneurosurgery (65% vs. 34%) (Stummer et&#xD;
      al., Lancet Oncology 2006).&#xD;
&#xD;
      Patients with presumed newly-diagnosed glioma will be entered into the trial. On the basis of&#xD;
      their expected extent of resection (low vs. high), they will be stratified in one of 2 groups&#xD;
      - Group 1 (expected high extent or resection) or Group 2 (expected low extent of resection).&#xD;
      Following stratification, patients with newly-diagnosed disease will be randomized to receive&#xD;
      either study drug (5-ALA/Gliolan®) or placebo (ascorbic acid) prior to surgery. Those who&#xD;
      have had previous biopsy only without further treatment will be eligible for randomization.&#xD;
      Intraoperatively, 5-ALA/Gliolan® patients will undergo resection with combined fluorescence&#xD;
      microscopy and confocal microscopy. Placebo patients will undergo resection with standard&#xD;
      light microscopy. Postoperatively, patients will have an MRI scan with and without contrast&#xD;
      within 48 hours of surgery. Subsequent analysis of each patient will include assessment of&#xD;
      the primary endpoint, that is,volume of residual disease (VRD) by volumetrically quantifying&#xD;
      the tumor before and after surgery using T1-weighted contrast-enhancement (high-grade&#xD;
      gliomas) or T2-weighted hyperintensity (low-grade gliomas). Similarly, volumetric extent of&#xD;
      resection will also be measured. Other secondary endpoints will include overall survival&#xD;
      (OS), progression-free survival (PFS), and National Institute of Health Stroke Scale (NIHSS)&#xD;
      (collected at baseline, 7-10 days post-op and at 6, 12, 18, and 24 months post op).&#xD;
&#xD;
      The Barrow 5-ALA Intraoperative Confocal (BALANCE) study will quantify the impact of&#xD;
      5-ALA/Gliolan(R) on low- and high-grade glioma extent of resection. To enhance the efficacy&#xD;
      of 5-ALA/Gliolan(R), particularly for low-grade gliomas that fluoresce less vigorously due to&#xD;
      their comparatively lower cellular metabolism, intraoperative confocal microscopy will be&#xD;
      used to amplify microscopic fluorescence at the tumor margins. The investigators' hypothesis&#xD;
      is that, for both low- and high-grade gliomas, 5-ALA/Gliolan(R) fluorescence in conjunction&#xD;
      with intraoperative confocal microscopy will significantly lower the VRD.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
      1. To determine the impact of intraoperative fluorescence and confocal microscopy on the&#xD;
      volume of residual disease following resection of a newly-diagnosed glioma.&#xD;
&#xD;
      Sub-goals:&#xD;
&#xD;
        1. To assess the feasibility and utility of combining intraoperative fluorescence with&#xD;
           confocal microscopy.&#xD;
&#xD;
        2. To determine the impact of this combined approach in improving volumetric extent of&#xD;
           resection.&#xD;
&#xD;
        3. To determine the impact of this combined approach in improving overall survival and&#xD;
           6-month progression-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric extent of resection</measure>
    <time_frame>Change in MRI from pre-operative to within 48 hours post-operative</time_frame>
    <description>Volumetric analysis of MRI contrast T1-weighted images (for low grade gliomas) will be compared to the preoperative sequences to calculate the volume of residual disease. Slice-by-slice assessment of pre- and postoperative tumor volume will be quantified by sequentially measuring the area of tumor on each slice and then integrating the combined measurements. This methodology has been previously reported (Sanai et al., Journal of Neurosurgery, 2010; Sanai et al, The New England Journal of Medicine, 2008)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival rate(OS)</measure>
    <time_frame>Time from randomization until date of death assessed up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate (PFS)</measure>
    <time_frame>Time from randomization until first date of progression assessed up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Change in score from pre-operative at post-operative, 6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>5-ALA/Gliolan® /5-Aminolevulinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - ascorbic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Aminolevulinic acid (ALA)</intervention_name>
    <description>Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)</description>
    <arm_group_label>5-ALA/Gliolan® /5-Aminolevulinic acid</arm_group_label>
    <other_name>5-Aminolevulinic acid Hydrochloride</other_name>
    <other_name>Gliolan®</other_name>
    <other_name>5-ALA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - ascorbic acid</intervention_name>
    <description>Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.</description>
    <arm_group_label>Placebo - ascorbic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presumed newly-diagnosed supratentorial glioma (previous biopsy-only/no adjuvant&#xD;
             therapy are eligible for randomization)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Normal bone marrow function (WBC &gt; 3000, Platelets &gt; 100,000)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infratentorial tumors&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hypersensitivity to 5-aminolevulinic acid hydrochloride or porphyrins&#xD;
&#xD;
          -  History of photosensitivity, porphyria, or exfoliative dermatitis&#xD;
&#xD;
          -  Hepatic dysfunction in the last 12 months (defined by AST, ALT, ALP, bilirubin &gt; 2.5 x&#xD;
             normal)&#xD;
&#xD;
          -  Serum creatinine &gt; 180 µmol/L&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt; 60 ml/min/1.73m2&#xD;
&#xD;
          -  Inability to undergo MRI scan with contrast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Sanai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital Medical Center, Phoenix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norissa Honea, RN, PhD</last_name>
    <phone>602-406-6267</phone>
    <email>Norissa.Honea@dignityhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center/Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norissa Honea, RN, PhD</last_name>
      <phone>602-406-6267</phone>
      <email>Norissa.Honea@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nader Sanai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Nakaji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Porter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taro Kaibara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kris Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Garrett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Little, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Wanebo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sanai N, Snyder LA, Honea NJ, Coons SW, Eschbacher JM, Smith KA, Spetzler RF. Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg. 2011 Oct;115(4):740-8. doi: 10.3171/2011.6.JNS11252. Epub 2011 Jul 15.</citation>
    <PMID>21761971</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2011</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extent of resection</keyword>
  <keyword>Glioma</keyword>
  <keyword>5-ALA</keyword>
  <keyword>tumor fluorescence</keyword>
  <keyword>confocal microscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

